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What to do with the patient with a 
positive HCV antibody test 
Daniel L. Phillips MD 
A test to measure hepatitis C antibody has recently been 
developed. The development of the antibodv test was closelv 
followed by the publication of two trials which demonstrated 
the efficacy of interferon a/fa in the treatment of transfusion-
associated hepatitis C. The author discusses management of 
the patient with a positive hepatitis C virus ( HCV) antibodv 
test, including an approach to sorting out those patients wh'a 
have false positive tests, information about modes of transmis-
sion for those patients who are asymptomatic carriers, and 
guidelines to determine which patients may be candidates for 
interferon therapy. 
Physicians will begin to hear from more and more patients 
who have been found to have antibody to hepatitis C virus. 
These individuals understandably will be concerned about the 
implications of their positive test. It is the obligation of their 
personal physicians to address that concern, decide whether 
further investigation is necessary and plan an evaluation when 
it is appropriate. It is the purpose of this article to make this 
task easier. 
There are two test kits used by the main laboratories in 
Hawaii to determine the presence of HCV antibody. They are 
made by different manufacturers. The Ortho Diagnostic Sys-
tems (ELISA) assay is used by the Blood Bank of Hawaii; the 
Abbott Labs (EIA) assay is used by Diagnostic Laboratory 
Services (DLS); and by SmithKiine Beecham (Accupath) 
Labs. 
Although the mechanics of how the tests are performed are 
different, both kits are based on work done at Chiron Corpora-
tion laboratories. In 1989 researchers there reported the isola-
tion of non-A non-B (NANB) hepatitis v!ral RNA, made 
cloned DNA, produced polypeptide that coded by this DNA 
and identified antibody against this polypetide in patients with 
NANB hepatitis'-2• The commercially available test kits use an 
enzyme-linked immunoassay technique to identify circulating 
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antibody to this HCV specific polypeptide. 
There are several important facts to be realized about the 
anti-HCV test: 
I) Antibody to HCV develops in approximately 50% of 
patients with acute hepatitis C and most lose the antibody 
after the acute illness resolves. In contrast, patients with 
chronic hepatitis C have persistent antibody. Thus, the pres-
ence of antibody to HCV does not generally represent immu-
nity, but more often suggests chronic infection'-<5 . 
2) There is a significant false positive rate. As many as 30 
to 60% of positive ELISA tests found among blood donors in 
Hawaii are thought to be false positives". Furthermore, 
patients with autoimmune hepatitis and paraproteinemias are 
said to have a high frequency of false positive tests7·x·•. 
3) There is a significant false negative rate. Approximately 
20% of all cases of post-transfusional hepatitis will have a 
negative test for HCV antibody. Part of this 20% is accounted 
for by another hepatitis virus (neither A, B, nor C), but it is 
clear that the HCV antibody test may fail to identify patients 
who unequivocally have hepatitis C. There are at least two 
reasons this occurs. Some patients may take up to one year, or 
fail altogether, to develop HCV antibody despite having epi-
demiologic evidence of having post-transfusional hepatitis C. 
Alternatively, the available commercial assays may be insuffi-
ciently sensitive to identify individuals with low titers of anti-
body4·10. 
The problem of false positive ELISA tests has lead to the 
development of other techniques to identify and confirm anti-
HCV positive patients. The best studied of these is the recom-
binant immunoblot assay (RIBA) which has not yet been 
approved for clinical use by the FDA Reports suggest that 
patients who are ELISA and RIBA positive are more likely to 
have HCV hepatitis than patients who are positive for the 
ELISA assay only''-' 2• 
However, it is important to realize that both false positives 
and false negatives may occur despite the results of the 
ELISA and RIBA assays. The Blood Bank of Hawaii auto-
matically sends all ELISA positive specimens to a reference 
lab for RIBA testing. DLS found that specimens strongly pos-
itive on the initial EIA assay, in tjleir patient population, near-
ly always had positive supplemental tests and, therefore, it 
sends only specimens which are weakly positive on EIA for 
additional testing. SmithKiine Beecham does not do supple-
mentary testing for specimens found positive on the initial 
EIA assay. 
So what are we to do with the patient who is found to be 
HCV positive? 
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The first step is to do a careful history and physical exami-
nation in looking for risk factors for HCV and signs and 
symptoms of chronic liver disease. A history of prior blood 
product transfusion, i.v. drug use, multiple sexual partners or 
sexual contact with a person with hepatitis, membership in a 
household where another individual has hepatitis, as well as 
employment as a health-care worker, have all been suggested 
as risk factors for HCV. 
The second step is to determine the serum ALT. If there are 
no apparent risk factors for hepatitis C; if the ALT is normal 
and if RIBA testing was negative, the most likely explanation 
is that the HCV antibody test was a false positive. However, 
because hepatitis C is typically associated with irregular ele-
vations of transaminases, and since liver disease has been 
observed to occur in patients with transiently normal ALTs; 
one should repeat the ALT every 3 months (Esteban-Mur 11, 
Second International Symposium on HCV, Los Angeles, 
November 1990). If the ALT is persistently normal for a year, 
no further follow-up is needed. 
In the same case (anti-HCV positive, normal ALT), if the 
RIBA test was positive, the patient may have recovered from 
hepatitis C but unlike most patients, has persistent antibody. 
Alternatively, the patient may be an asymptomatic carrier. The 
appropriate response is to monitor the ALT periodically to be 
sure that it is persistently normal. 
One should also advise that the patient may be an infec-
tious carrier in order to educate him or her about presumed 
modes of transmission. We know that parenteral transmission 
is the most frequent, but other modes of transmission must 
exist, as at least 40% of patients do not have a recognized risk 
factor for hepatitis C'3• 
The role of sexual transmission is unclear. The homosexual 
population does not appear to be at increased risk for HCV 
hepatitis and spouses of patients with hepatitis C do not have a 
higher than expected rate of antibodies to HCV 14•15• On the 
other hand, there is a report that more patients with NANB 
hepatitis have a history of multiple sexual partners or sexual 
contact with someone with a history of hepatitis than does a 
control population'". Thus it is prudent to advise patients to 
use safer sexual practices until further information is available. 
Maternal-neonatal transmission has been reported to occur 
50% of the time but does not result in chronic hepatitis in the 
infant'\ as reported by Roggendorf at the Second International 
Symposium on HCV. 
When the patient is anti-HCV positive and has an abnormal 
ALT, other causes of liver disease must be sought because of 
the chance of a false-positive antibody test. Diseases that 
should be considered include hepatitis B, hemochromatosis, 
Wilson's disease, alpha I antitrypsin deficiency, autoimmune 
hepatitis, primary biliary cirrhosis, primary sclerosing cholan-
gitis, drug hepatotoxicity, fatty liver, alcohol-induced liver 
disease, thyroid disease, syphilis and infiltrating processes. 
Appropriate serologic tests and an imaging study such as 
ultrasound or CT-scan should be considered. The patient 
should have ALTs rechecked every 2 months. If the ALT 
returns to normal and stays normal over the course of a year, 
the patient may have recovered from hepatitis C, or may have 
become a chronic asymptomatic carrier. These patients need 
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to receive the information about disease transmission as 
described above and should have a repeat ALT every 6 to 12 
months. 
What then about the patient who is HCV positive and has a 
persistently or intermittently abnormal ALT over a period 
greater than 6 months? If a thorough evaluation has ruled out 
other causes of liver disease, and the patient has a positive 
RIBA test, it may be assumed that the patient has chronic hep-
atitis C. The question then becomes what if anything should 
be done about it? To answer this, one must first understand the 
natural history of untreated chronic hepatitis C and what 
potential treatment there is to offer. 
We know that at least 20% of patients with chronic hepati-
tis C will eventually develop cirrhosis!). Furthermore, there is 
increasing evidence that chronic hepatitis C is associated with 
the development of hepatoma 18•1". Treatment that eliminates 
the carrier state is the ultimate goal and would theoretically 
prevent the development of cirrhosis and hepatocellular carci-
noma. Until recently, there was no test for the presence of 
viral RNA (although PCR technology has made this now pos-
sible on a research basis). Investigators therefore have relied 
on a normal ALT and improvement in hepatic histology as 
markers of successful treatment. 
Studies on treatment with acyclovir and steroids in patients 
with chronic NANB hepatitis have found that neither drug is 
effective20•21 • On the other hand, 2 randomized controlled trials 
have recently shown that interferon is effective in controlling 
disease activity in a significant number of patients with chron-
ic hepatitis C2w. These trials used interferon at doses of I, 2, 
and 3-million units given 3 times weekly for 24 weeks. The 
response rates (normalization of serum ALT) were 28%, 48%, 
and 46% respectively with a I 0% placebo response. 
Improvement in liver histology was also seen. Unfortunate-
ly, only 20 to 50% of those whose ALT values become nor-
mal, maintained those values over the 6 to 12 month follow-
up after treatment ended. Side effects were common and 
included flu-like symptoms, diarrhea, mild alopecia and occa-
sional thrombocytopenia; but dose reduction or withdrawal 
from the study was rarely required. Future trials will focus on 
finding the ideal dose and duration of treatment to improve 
response rates and remission maintenance. 
The patient with chronic hepatitis C should, therefore, be 
advised not only how to prevent further transmission of the 
disease but also of the option of treatment with interferon. 
Some clinicians would argue that the long-term effects of 
treatment with interferon for this disease are not well enough 
known to be recommended for anyone (Koretz RL, comment 
in Hepatology 1990; 12:613-615). However, the FDA has 
recently approved interferon for use in hepatitis C. Given the 
significant incidence of an adverse outcome in untreated dis-
ease, many patients will wish to consider this potentially ben-
eficial treatment for themselves. 
Which patient with hepatitis C is a candidate for treatment 
with interferon? Treatment criteria at a minimum should 
include: A pretreatment liver biopsy that shows chronic per-
sistent or chronic active hepatitis and/or cirrhosis; at least 6 
months of documented elevation of ALT greater than 1.5X 
normal; careful exclusion of other causes of liver disease; no 
history of CNS trauma, depression or other major medical ill-
ness; a normal creatinine; age greater than 18 and not preg-
nant; HIV and HBsAg negative, WBC >3,000, platelet count 
> 70,000, stable liver disease (ie, no evidence of ascites, 
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encephalopathy or variceal bleeding, bilirubin <2.0, prothrom-
bin time <3 seconds greater than control); normal TSH and 
T4, and HCV antibody-positive confirmed by RIBA. 
Should a decision to treat be made, the Davis and Di Bis-
ceglie trials suggest that 3-million units of interferon be 
administered subcutaneously 3 times a week as the appropri-
ate treatment regimen. 
However, the optimal dosage of interferon has yet to be 
defined. No one knows yet how the drug will work in 
Hawaii's ethnically diverse population, and there are no data 
on what to do for those who fail to respond initially or who 
relapse on termination of therapy. Furthermore, the drug car-
ries with it potential toxicity, and much remains to be learned 
about the natural history of treated and untreated disease. 
We believe, therefore, that physicians who plan to use 
interferon on patients should follow specific treatment guide-
lines, enroll patients in controlled trials when such trials are 
available, and that data on patients should be collected and 
recorded in order to help answer the many questions about 
hepatitis C and its treatment. 
The Liver Research Group of Hawaii was created to 
answer this need (see the appendix below). 
APPENDIX 
In the fall of 1990, a group of physicians interested in the 
treatment of patients with liver disease came together and, 
with assistance from the Cedars-Sinai Medical Center in 
Los Angeles and the Cancer Research Center of Hawaii, 
formed the Liver Research Group. It is the intent of this 
group to make the latest treatments for chronic liver dis-
ease available to patients in Hawaii. The Liver Research 
Group encourages physicians who take care of these 
patients to contact its office at the Cancer Research Center 
(548-8545) for further information about enrolling patients in 
clinical trials or obtaining specific guidelines for the use of 
recently approved treatments such as interferon in chronic 
hepatitis C. 
The 1990s have seen an explosion of knowledge about 
Hepatitis C. We now have potentially an exciting treatment for 
this previously untreatable condition. We in Hawaii are in a 
position to add to this fund of knowledge as well as offer our 
patients state-of-the-art care. However, we must recognize our 
responsibility to "first do no harm", treat according to the best 
scientific principles, and where knowledge is deficient, to col-
lect data so we can care for future patients more effectively. 
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For readers interested in further information, the charter of 
the Hawaii Liver Research Group follows: 
Chronic Liver Disease Research Group 
The Chronic Liver Disease Research Group will be est~lished to 
foster the study of treatment and prevention of chronic liver disease 
and its consequences. Of particular interest to the group are treat-
ments which interrupt the progression of chronic viral hepatitis to cir-
rhosis and hepatocellular carcinoma. The group will also help advise 
those individuals involved in the care of patients who are candidates 
for liver transplantation. 
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Background: 
The initial funding for the research group has been made possible 
by a donation from the Cedars-Sinai Medical Center. This funding 
includes money for salary and overhead for a nurse study coordina-
tor. The nurse coordinator will be based at the Cancer Research Cen-
ter in Honolulu, Hawaii. 
The need for such a research group is clear. I) Hawaii's unique 
ethnic diversity, relative geographic isolation and high carrier rate for 
hepatitis B, make it an ideal place to study the effects of potential 
treatment and natural history of chronic liver disease. 2) Several 
potential treatments for liver disease for which we have had nothing 
to offer before, are now in the process of development. These treat-
ments are promising enough that they should be made available at 
the earliest possible time to patients in Hawaii. However, these treat-
ments should be conducted in the setting of clinical trials until 
enough data has been generated to standardize their use. 3) No center 
is now performing liver transplantation in Hawaii. There is a need for 
a central repository of information about Mainland transplant centers. 
There is also a need to have personnel familiar with the pre-trans-
plant screening process and mechanics of referral for liver transplan-
tation. This would allow for the best use of the health care facilities 
in Hawaii before referral to Mainland centers for transplantation. 
Structure 
A nurse coordinator will be hired. This individual will be respon-
sible for maintaining records of ongoing research protocols. The 
nurse coordinator will remain in contact with the originating investi-
gator. By going to physician offices, helping to draw blood if neces-
sary and gathering data from the individual physicians, the N-C will 
facilitate the broader availability of treatment protocols while making 
it possible to study treatment strategies in a useful and meaningful 
way. The N-C will make sure that the protocols are being followed 
correctly and will send data to the original investigator. The N-C will 
be responsible for making the availability of research protocols wide-
ly known to physicians in the community. The N-C will help in pro-
cessing protocols through any appropriate institutional review board. 
The activities of the nurse will be supervised by the chairman of 
the Chronic Liver Disease Research Group. This chairman will be 
appointed by committee. The committee will be composed of inter-
ested individuals representing a broad spectrum of physicians 
involved in the treatment of patients with chronic liver disease. In 
addition to electing a chairman, the committee will encourage inves-
tigators to submit research protocols for approval. Approved proto-
cols will be eligible for assistance from the N-C. The committee will 
approve protocols on the basis of the following priorities: 
I) Scientific merit. 
2) The applicability of the research to patients in Hawaii. 
3) The uniqueness of the research proposal. 
4) The potential benefit of the treatment. As an example: a pro-
posal for a promising treatment in a condition for which there is now 
no effective treatment would receive a priority rating. 
5) The proposal must have received approval from an institutional 
review board most appropriate to the individual(s) originating the 
proposal. 
A reassessment of ongoing protocols at 6 months will be under-
taken by the committee to ensure that the original approval is still 
appropriate. 
Final comments 
The funding for this organization has come from the Cedars-Sinai 
Medical Center. Academic support and a number of research proto-
cols will also be provided by Cedars-Sinai Medical Center. However. 
the committee will consider proposals from other investigators in 
Hawaii and from other institutions based on the clements described 
above. Should .patients involved in treatment protocols require liver 
transplantation, the personal physician will retain the right to refer 
the patient for whatever treatment and to whatever institution the 
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physician feels is in the best interest of the patient. 
The funding is for one year. At the end of that time the relation-
ship with Cedars-Sinai Medical Center and the performance of the 
liver research group will be reevaluated. It is hoped that this relation-
ship will have been a productive one and that the funding and aca-
demic support will be continued. It is also hoped that other sources of 
funding may also be found which would allow for a greater scope of 
activity, and the creation of a permanent entity, The Liver Research 
Center. 
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